2019
AlPharma has conducted R&D of new drugs with a new combination of molecules for the registration in Russia.
Managing a number of scientific and investment projects, including research and development of the first unique inhibitor-protected antibiotic on a global scale.
AlPharma took part in the organization and holding of scientific and practical conferences in various cities of Russia, which were attended by more than 2500 participants.
2017-2018
Successful registration of anti-infective drugs in Russia of the 3rd and 4th generation of the cephalosporin group that is Klaructam® and Maxictam®-AF.
2015-2016
AlPharma started cooperation with new international partners Sandoz and AstraZeneca to promote and sell anti-infective drugs in the Russian Federation. The company had also been successful in its first clinical trials.
2013-2015
The company launched the process of registering new medicines in the Russian Federation and began conducting preclinical and clinical trials (phase III) of several anti-infective drugs.
2011-2012
AlPharma opened representative offices in St. Petersburg, Krasnodar, Samara, and other cities within the framework of the sales development project in the central region of Russia.
2009-2010
AlPharma began marketing and promoting of its anti-infective drugs under an international contract with a strategic partner Lupine Ltd.
2007-2008
AlPharma concluded its first contracts with pharmaceutical manufacturers in Russia and abroad i.e., Orchid Healthcare, Lupin Ltd, Deco LLC, Sintez OJSC, Biosintez OJSC.
2005-2006
AlPharma opened a pharmaceutical warehouse and began to supply its products to hospitals in Moscow.
2004
AlPharma is a Russian pharmaceutical manufacturer with the headquarters in Moscow that is producing both Original and Generic Injectable Combined Antibacterial Medicines of broad spectrum of action.
Currently, the company sells and exports its products both in Russia and abroad.